/TLRY
TLRY Stock - Tilray Brands, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$11.16-9.56%
$1.18 (-9.56%) • Dec 19
44
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.68
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).29
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.35
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-10.4%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TLRY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.05 – $11.27
TARGET (TP)$10.00
STOP LOSS$10.27
RISK/REWARD1:-1.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.13
52W High$23.20
52W Low$3.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.13B | $1.07B | $844.72M | $792.12M | $619.67M |
| Gross Profit | $330.11M | $304.33M | $197.95M | $147.26M | $148.77M |
| Gross Margin | 29.3% | 28.3% | 23.4% | 18.6% | 24.0% |
| Operating Income | $-3,132,304,973 | $-238,102,294 | $-1,844,929,170 | $-769,461,327 | $-159,627,762 |
| Net Income | $-3,000,620,016 | $-333,803,761 | $-1,956,688,894 | $-601,047,393 | $-443,747,813 |
| Net Margin | -266.3% | -31.1% | -231.6% | -75.9% | -71.6% |
| EPS | $-33.80 | $-4.50 | $-31.70 | $-11.30 | $-15.10 |
Company Overview
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
1
50%
Sell / Underperform
1
50%
Analyst Consensus🔴 Bearish
0 Bullish2 Neutral/Bearish
Price Targets
$3
Average Target
↓ 71.2% Downside
Now
$3
Low
$3
Average
$4
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 5th 2024 | Alliance Global Partners | Reiterated | Neutral | $2.75← $2.25 |
| November 2nd 2022 | Bernstein | Initiation | Market Perform | $3.9 |
| July 29th 2022 | The Benchmark Company | Downgrade | Sell | $3 |
Earnings History & Surprises
TLRYBeat Rate
28%
Last 18 quarters
Avg Surprise
-42.6%
EPS vs Estimate
Beats / Misses
5/13
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 24
-11.6%
$-0.07vs$-0.06
Q2 24
-140.0%
$-0.12vs$-0.05
Q3 24
-81.8%
$-0.04vs$-0.02
Q4 24
-11.1%
$-0.04vs$-0.04
Q1 25
-150.0%
$-0.10vs$-0.04
Q2 25
-150.0%
$-0.10vs$-0.04
Q3 25
+166.7%
$0.02vs$-0.03
Q4 25
+98.4%
$-0.00vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 6, 2026 | — | — | — | — |
Q1 2026 | Jan 9, 2026 | $-0.14 | — | — | — |
Q4 2025 | Oct 9, 2025 | $-0.27 | $-0.00 | +98.4% | ✓ BEAT |
Q3 2025 | Jul 28, 2025 | $-0.03 | $0.02 | +166.7% | ✓ BEAT |
Q2 2025 | Apr 8, 2025 | $-0.04 | $-0.10 | -150.0% | ✗ MISS |
Q1 2025 | Jan 10, 2025 | $-0.04 | $-0.10 | -150.0% | ✗ MISS |
Q4 2024 | Oct 10, 2024 | $-0.04 | $-0.04 | -11.1% | ✗ MISS |
Q3 2024 | Jul 29, 2024 | $-0.02 | $-0.04 | -81.8% | ✗ MISS |
Q2 2024 | Apr 9, 2024 | $-0.05 | $-0.12 | -140.0% | ✗ MISS |
Q1 2024 | Jan 9, 2024 | $-0.06 | $-0.07 | -11.6% | ✗ MISS |
Q4 2023 | Oct 4, 2023 | $-0.05 | $-0.10 | -100.0% | ✗ MISS |
Q3 2023 | Jul 26, 2023 | $-0.05 | $-0.15 | -200.0% | ✗ MISS |
Q2 2023 | Apr 10, 2023 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q1 2023 | Jan 9, 2023 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q4 2022 | Oct 7, 2022 | $-0.06 | $-0.08 | -33.3% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $-0.07 | $-0.34 | -385.7% | ✗ MISS |
Q2 2022 | Apr 6, 2022 | $-0.08 | $0.04 | +150.0% | ✓ BEAT |
Q1 2022 | Jan 10, 2022 | $-0.09 | $0.03 | +133.3% | ✓ BEAT |
Q4 2021 | Oct 7, 2021 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $-0.08 | $-0.11 | -37.5% | ✗ MISS |
Latest News
Marijuana stocks sell off as Trump signs executive order to reclassify cannabis
📉 NegativeDowjones•Dec 18, 2025, 09:24 PM•Also: , ,
Cannabis stocks selling off as Trump signs rescheduling order
📉 NegativeSeeking Alpha•Dec 18, 2025, 07:21 PM•Also: , ,
Tilray Brands Announces Formation Of Tilray Medical USA, Inc.; Confirms Strategic Framework For U.S. Medical Cannabis Operations
📈 PositiveBenzinga•Dec 18, 2025, 07:11 PM
U.S. Centers For Medicare & Medicaid Services Administrator Says Millions Of Americans On Medicare To Become Eligible To Receive CBD As Early As April
📈 PositiveBenzinga•Dec 18, 2025, 06:59 PM•Also: , ,
Trump Order Will Direct Maintaining Restrictions On Dangerous Products; Centers For Medicare & Medicaid Services Plans To Allow Beneficiaries To Benefit From Hemp-derived Cbd Products At No Cost; Trump Order Will Not Encourage Use, But Recognizes Potential Both Therapeutic Uses And Risks Like Addiction; Marijuana Will Remain Illegal To Possess Under Federal Law; Trump Order Makes No Changes To Criminal Penalties Or Access For Recreational Use Of Marijuana
➖ NeutralBenzinga•Dec 18, 2025, 06:51 PM•Also: , ,
Trump To Sign Executive Order On Thursday Aiming To Expedite Reclassification Of Marijuana As Schedule III Substance; Trump Order Will Allow More Research Of Medical Marijuana And Cannabidiol; Trump Order Will Help U.s. To Better Understand Risks Associated With Marijuana; There Is Currently Insufficient Evidence Of Marijuana's Medical Uses; Trump Order Will Direct White House To Work With Congress To Improve Access To Hemp-Derived CBD Products
📈 PositiveBenzinga•Dec 18, 2025, 06:49 PM•Also: , ,
'Trump's Marijuana Rescheduling Order Could Include Industry Banking And CBD Medicare Coverage Provisions, Sources Say;'- Marijuana Moment
📈 PositiveBenzinga•Dec 17, 2025, 05:01 PM•Also: , ,
'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News
📈 PositiveBenzinga•Dec 17, 2025, 09:12 AM•Also: , ,
Shares of cannabis-linked stocks are trading higher after President Donald Trump confirmed his administration is strongly considering reclassifying marijuana.
📈 PositiveBenzinga•Dec 16, 2025, 07:17 PM•Also: , ,
Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance
📈 PositiveBenzinga•Dec 15, 2025, 08:48 PM•Also: , ,
President Trump Says Considering Executive Oder To Reclassify Marijuana
➖ NeutralBenzinga•Dec 15, 2025, 08:45 PM•Also: , ,
Tilray shares are trading lower, pulling back after recent cannabis strength.
📉 NegativeBenzinga•Dec 15, 2025, 04:18 PM
Tilray's stock takes off on news of Trump's softening cannabis stance
📈 PositiveDowjones•Dec 12, 2025, 10:44 PM
Shares of cannabis-linked stocks are trading higher following a report suggesting that President Trump is expected to reclassify marijuana as a Schedule III drug.
📈 PositiveBenzinga•Dec 12, 2025, 01:23 PM•Also: , ,
Tilray's Redecan Brand Launches New 'Liquid Diamond' Vapes Across Canada
📈 PositiveBenzinga•Dec 11, 2025, 12:09 PM
'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment
➖ NeutralBenzinga•Dec 4, 2025, 01:59 PM•Also: , ,
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 2, 2025, 01:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 2, 2025, 12:50 AM
Tilray Brands shares are trading lower after the company recently announced a 1-for-10 reverse stock split.
📉 NegativeBenzinga•Nov 28, 2025, 03:09 PM
Tilray Brands shares are trading lower after the company announced a 1-for-10 reverse stock split.
📉 NegativeBenzinga•Nov 26, 2025, 09:11 PM
Frequently Asked Questions about TLRY
What is TLRY's current stock price?
Tilray Brands, Inc. (TLRY) is currently trading at $11.16 per share. The stock has moved -9.56% today.
What is the analyst price target for TLRY?
The average analyst price target for TLRY is $10.00, based on 1 analyst.
What sector is Tilray Brands, Inc. in?
Tilray Brands, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is TLRY's market cap?
Tilray Brands, Inc. has a market capitalization of $1.25 billion, making it a small-cap company.
Does TLRY pay dividends?
No, Tilray Brands, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.90
Mkt Cap: $1.5B
AMPH
Amphastar Pharmaceuticals, Inc.
$26.60
Mkt Cap: $1.2B
DVAX
Dynavax Technologies Corporation
$10.86
Mkt Cap: $1.3B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
HROW
Harrow Health, Inc.
$46.40
Mkt Cap: $1.7B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NEOG
Neogen Corporation
$7.20
Mkt Cap: $1.6B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PAHC
Phibro Animal Health Corporation
$37.25
Mkt Cap: $1.5B
Explore stocks similar to TLRY for comparison